Cerus Corporation

Click here to visit Sponsor’s website

Cerus’ INTERCEPT Blood System reduces the risk of transfusion- transmitted disease by inactivating a broad range of viruses, bacteria and parasites that may be present in donated blood. INTERCEPT has been extensively proven with over ten years of use. Now over 100 centers throughout Europe and selected countries treat their platelet and/or plasma components. To date, kits have been sold to produce nearly 2,000,000 transfusable units. In the US, Cerus is seeking regulatory approval of INTERCEPT for plasma and platelets. The INTERCEPT red blood system is in development.

Join Mailing List

Tif2013 Subscription